Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 16, 2018

Boehringer, Epizyme announce $300m oncology therapy program

Boehringer Ingelheim has entered into a new global collaboration with Epizyme to develop novel epigenetic oncology therapies.

Boehringer, Epizyme announce $300m oncology therapy program